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Abstract
A homozygous mutational change in the Ataxia-Telangiectasia and RAD3 related (ATR) gene was previously reported in two
related families displaying Seckel Syndrome (SS). Here, we provide the first identification of a Seckel Syndrome patient with
mutations in ATRIP, the gene encoding ATR–Interacting Protein (ATRIP), the partner protein of ATR required for ATR stability
and recruitment to the site of DNA damage. The patient has compound heterozygous mutations in ATRIP resulting in
reduced ATRIP and ATR expression. A nonsense mutational change in one ATRIP allele results in a C-terminal truncated
protein, which impairs ATR–ATRIP interaction; the other allele is abnormally spliced. We additionally describe two further
unrelated patients native to the UK with the same novel, heterozygous mutations in ATR, which cause dramatically reduced
ATR expression. All patient-derived cells showed defective DNA damage responses that can be attributed to impaired ATR–
ATRIP function. Seckel Syndrome is characterised by microcephaly and growth delay, features also displayed by several
related disorders including Majewski (microcephalic) osteodysplastic primordial dwarfism (MOPD) type II and Meier-Gorlin
Syndrome (MGS). The identification of an ATRIP–deficient patient provides a novel genetic defect for Seckel Syndrome.
Coupled with the identification of further ATR–deficient patients, our findings allow a spectrum of clinical features that can
be ascribed to the ATR–ATRIP deficient sub-class of Seckel Syndrome. ATR–ATRIP patients are characterised by extremely
severe microcephaly and growth delay, microtia (small ears), micrognathia (small and receding chin), and dental crowding.
While aberrant bone development was mild in the original ATR–SS patient, some of the patients described here display
skeletal abnormalities including, in one patient, small patellae, a feature characteristically observed in Meier-Gorlin
Syndrome. Collectively, our analysis exposes an overlapping clinical manifestation between the disorders but allows an
expanded spectrum of clinical features for ATR–ATRIP Seckel Syndrome to be defined.
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Introduction
Seckel Syndrome (SS) (OMIM 216000) is an autosomal
recessive disorder characterised by marked microcephaly, intra-
uterine and post-natal growth retardation, developmental delay
and characteristic facial features, encompassing micrognathia
(small and receding chin), receding forehead and pronounced
nose [1]. Majewski (microcephalic) osteodysplastic primordial
dwarfism (MOPD) type II and Meier-Gorlin Syndrome (MGS)
also display microcephaly and primordial dwarfism [2,3]. How-
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ever, each of these disorders display an additional spectrum of
features conferring clinical distinction. Despite this, on an
individual basis, assigning patients to a specific classification is
difficult. Additionally, primary microcephaly represents a disorder
displaying pronounced microcephaly without marked impact on
growth [4]. Five loci conferring SS have been described with four
genes identified [5,6]. The first causal genetic defect identified for
SS was the Ataxia-Telangiectasia and RAD3 related (ATR) gene [7]. A
homozygous mutation in ATR was identified in two related SS
families and cell-based studies provided strong evidence for an
impact on ATR function in patient cell lines. This sub-class of SS
was designated ATR–SS. More recently, mutations in CTIP were
identified in a SS patient as well as in a family described as
displaying Jawad Syndrome [8]. Additionally, mutations in
CENPJ and CEP152, two centrosomal proteins, have been
described in SS patients, although mutations in these genes more
frequently confer primary microcephaly [9,10]. Mutations in
PCNT, which encodes a centrosomal protein, and ORC1L, a
component of the original licensing complex, were reported in
patients originally classified as SS although in both cases
retrospective analysis revealed that such mutations more frequent-
ly cause MOPD type II or MGS, respectively, highlighting the
diagnostic challenge faced in the clinic [11–15]. These studies
demonstrate that evaluation of multiple patients is required to
provide insight into the spectrum of clinical features conferred by
specific gene defects, which ultimately aids an understanding of the
role of the defective protein during development. To date all
ATR–SS patients belong to one of two related families, which
harbour the identical homozygous mutation in ATR, thereby
limiting the characterisation of the clinical phenotype conferred by
ATR deficiency. Furthermore, no patients deficient in ATR
interacting protein, ATRIP, which is required for ATR stability,
have hitherto been described.
ATR, like the related Ataxia-Telangiectasia mutated (ATM)
protein, is a phosphoinositol-3 kinase (PI3)-like kinase that
functions at the centre of a signal transduction network activated
by DNA damage, and most importantly, by replication fork
stalling [16]. ATR and ATM share phosphorylation targets but
whilst ATM is activated by DNA double strand breaks (DSBs) that
arise, for example, following exposure to ionising radiation (IR),
ATR is activated by single stranded (ss) regions of DNA that arise
following replication fork stalling or exposure to agents that induce
bulky DNA adducts [17,18]. Importantly, since replication fork
stalling occurs during most cycles of replication, ATR is essential.
ATM, in contrast, is non-essential presumably because endoge-
nous DSBs arise infrequently. ATR forms a stable complex with
ATR–interacting protein (ATRIP), which is required for ATR
stability [19]. Further, ATRIP is required for ATR localisation to
ssDNA regions and hence for ATR activation. Consequently, in a
range of organisms loss of ATRIP or its homologue, phenocopies
ATR deficiency [17,20–22]. Although ATM and ATR share
overlapping substrates, ATR specifically phosphorylates Chk1
whilst ATM phosphorylates the related kinase, Chk2. The major
functions of ATR are to activate cell cycle checkpoint arrest,
stabilise stalled replication forks and promote replication fork
restart, which is achieved through its ability to phosphorylate a
range of substrates including p53 and H2AX [18,23,24].
Interestingly, in the context of SS, CtIP promotes DNA end
resection, which leads to ss DNA formation, the lesion activating
ATR. Hence, CtIP functions in a mechanism leading to ATR
activation. It is noteworthy that cells derived from PCNT-mutated
MOPD type II patients are also defective in ATR–dependent G2/
M checkpoint arrest although upstream steps in the ATR–
signalling pathway are activated normally [11]. These findings
suggest that PCNT is required for an important end-point of ATR
function. Additionally, the origin licensing complex, components
of which are mutated in MGS, is required for the initiation of
replication and ORC1L-deficient MGS cell lines display slow S
phase progression [13]. Similarly, ATR promotes S phase
progression by facilitating recovery from replication fork stalling.
Together, these findings demonstrate mechanistic overlap between
ATR, PCNT and ORC1L, which may underlie some clinical
overlap in the disorders conferred by mutations in the genes
encoding these proteins.
Here, we provide the first description of a SS patient with
mutations in ATRIP. Interestingly, the mutational change in one
ATRIP allele causes impaired ATR–ATRIP interaction and our
extensive cellular analysis confirms a deficiency in ATR signalling
and damage responses. Additionally, we describe two further,
unrelated patients with mutations in ATR. The identification and
clinical description of an ATRIP patient and two further ATR
patients provides a more definitive characterisation of the clinical
phenotype conferred by ATR deficiency.
Results
Cells derived from patient CV1720 display a
compromised DNA damage response
Patient CV1720 displayed severe microcephaly, growth delay
and dysmorphic facial features and was classified as a SS patient
(see Table 1 and Figure S1A for details of the clinical features).
Cell line CV1720 is a lymphoblastoid cell line (LBL) derived from
the patient; fibroblasts were not available. Cells from the
previously described ATR–SS (DK0064) patient display impaired
DNA damage responses and phosphorylation of ATR substrates
[7]. To determine whether CV1720 cells are defective in ATR–
dependent G2/M checkpoint arrest, the mitotic index (MI) was
monitored at 2 h following UV exposure, a form of DNA damage
known to activate ATR–dependent checkpoint arrest. Whilst WT
LBLs show a significantly reduced MI following UV exposure
compared to undamaged cells, CV1720 cells showed only a
modest decrease similar to that observed in DK0064 (ATR–SS)
cells (Figure 1A). Cells from the parents of patient CV1720
Author Summary
Seckel Syndrome (SS) is a rare human disorder charac-
terised by small head circumference and delayed growth.
Patients can show additional features including abnormal
bone development, receding chins, sloping foreheads, and
small ears. In 2003, we identified ataxia telangiectasia and
Rad3 related (ATR) as a causal genetic defect in two related
families displaying SS. However, additional patients with
mutations in ATR have not hitherto been identified. Here,
we describe two further patients with novel mutations in
ATR. Additionally, we identify a patient with mutations in
ATRIP, which encodes an interacting partner of ATR,
representing a novel genetic defect causing SS. ATR
functions to promote the ability of cells to recover from
difficulties encountered during replication. We show that
patient-derived cells have reduced ATR and ATRIP protein
levels and defective ATR/ATRIP function. Our identification
of further ATR–ATRIP defective patients and a consider-
ation of their clinical features aids the characterisation and
identification of this form of SS and provides insight into
the role played by the ATR–ATRIP complex during
development.
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(CV1780 and CV1783) displayed normal G2/M checkpoint
arrest.
We have previously observed that cells from other SS patients
display defects in ATR–dependent G2/M checkpoint arrest but
activate upstream steps in the ATR signalling cascade normally
[25]. This is exemplified by cell lines from MOPD type II patients
with mutations in PCNT, which are defective in ATR–dependent
G2/M checkpoint arrest but proficient in ATR phosphorylation
events [11]. Therefore, next, we examined whether CV1720 LBLs
efficiently activate upstream steps in ATR signalling. Since these
assays predominantly reflect the response of replicating phase cells,
we first verified that CV1720 and control LBLs harbour a similar
percentage of S phase cells (Figure S2). Pan-nuclear phosphory-
lation of H2AX (cH2AX) after replication fork stalling represents
an ATR–specific damage response [24]. Strikingly, whilst expo-
sure to 5 mM HU for 2 h resulted in an elevated number of cells
staining positively for cH2AX in WT cells, this was not observed
in either CV1720 or DK0064 (ATR–SS) cells (Figure 1B). We
note that although previous studies have shown that ATM can be
activated and phosphorylate cH2AX at DSBs arising following
HU treatment in the absence of ATR due to enhanced fork
collapse, this was not observed at 2 h post 5 mM HU exposure in
these patient cells most likely due to residual ATR activity and/or
the early times examined [26,27]. Chk1 represents an important
ATR substrate required for G2/M checkpoint arrest. To examine
Chk1 activation, we carried out Western Blotting using p-Chk1
antibodies. Following the same UV exposure conditions (2 h post
5 Jm22) employed to examine G2/M checkpoint arrest, we
Table 1. Clinical features of ATR/ATRIP–deficient patients.
ATRIP–SS ATR–SS 27-4BI 19-8BI
Ethnicity Gujarati-Indian (consanguineous) Pakistani (consanguineous) English English
Birth.
OFC (cm) 27.1 24 (-8SD) 27 24.2
Wgt (Kg) 2.06 1.1 (-3SD) 1.15 0.77
Hgt (cm) NR NR 36 NR
Age. 14 mts 3 yrs 3 mts 9 yrs 20 mts 4.5 yrs
OFC (cm) -9SD -10SD -12SD -10SD -10SD
Wgt (Kg) -5SD -6SD -3.3SD -8SD -7SD
Hgt (cm) -5SD -6.5SD NR -8SD -8SD
Face Micrognathia, receding forehead,
prominent nose.
Micrognathia, receding
forehead, prominent nose.
Micrognathia, prominent
nose, hypoplastic alae
nasi, low set columella,
deep set short palpebral
fissures.
Micrognathia, blepharophimosis,
short palpebral fissures. Prominent
nose; high nasal bridge. High
anterior hairline.
Teeth Dental crowding. Dental crowding and
malocclution.
4 teeth at 20 months. Dental crowding.
Ears Small lobes. Posteriorly rotated with
absent lobes.
Small, round, low set
with poorly formed
antihelix tragus &
antitragus. Absent lobes.
Small ears with absent lobes
Hands Bilateral 5th finger clinodactyly. Multiple ivory epiphysis. Small, tapering fingers. Bilateral 5th finger clinodactyly. 5th
metacarpels appear short. Blue
colouration to both thenar eminence.
Skeletal Survey Delayed bone age (wrist & hips),
symmetric dwarfism.
Microcrania with fuse sutures.
Mild thoracic kyphosis. Ribs
angulated posteriorly. Narrow
iliac blades, cox valga and minor
subluxation of the hips. No
disslocation of the radial heads
Symmetric dwarfism.
Small patellae. No joint
hypermobility or
kyphoscoliosis.
Symmetric dwarfism. Copper beaten
skull. No ossification of the patellae
(age 4 yrs). Marked hip & shoulder
flexibility. No kyphosis.
Endo-crinology Normal IGF1, TFT, LH, FSH & cortisol. NA NA NA
MRI 14 mts:generalised cerebral atrophy,
normal ventricular systems. Delayed
myelination in the anterior limb of
the internal capsule. Pituitary is
present though of unusual shape
with absent fossa.
NA NA 2 yrs: abnormal gyration in posterior
aspect of the cingulated gyrus
extending into the parietal occipital
region. Hypoplastic corpus collasum.
Other NR Developmental delay.
Walked at 7 yrs.
No abnormal skin
pigmentation.
Small feet with
metatarsus adductus
No abnormal skin pigmentation.
Developmental delay. Sat at 15 mts,
walked at 3 yrs 10 mts. High pitched
voice, asthma, multiple chest infections,
feeding difficulties-reflux (gastrostomy
fed). Multiple liver cysts consistent with
Caroli’s disease found at 17 mts.
NR; not recorded. NA; not assessed.
doi:10.1371/journal.pgen.1002945.t001
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Figure 1. CV1720 cells show impaired ATR–dependent DNA damage responses. A) WT, DK0064 (ATR–SS), CV1720 (patient), CV1780
(patient’s mother) and CV1783 (patient’s father) cells were exposed to 5 Jm22 UV and the mitotic index (MI) assessed 2 h post exposure. A greater
than two fold decrease in mitotic index is observed in WT and both paternal cell lines but not in DK0064 (ATR–SS) or CV1720 (patient) cells. B) Cells
were exposed to 5 mM HU for 2 h and the percentage of p-H2AX (c-H2AX) positive cells assessed by immunofluorescence. Note that HU causes pan
nuclear p-H2AX formation rather than defined foci as observed after exposure to ionising radiation. Thus, the percentage of c-H2AX positive cells was
scored. C) Cells were exposed to UV (5 Jm22) and subjected to Western Blotting (WB) using p-Chk1 (p-Ser317) antibodies at 2 h. Chk1 expression was
shown to be similar in WT and patient cells (lower panel). D) Cells were exposed to 3 mM HU for 2 h and whole cell extracts analysed by WB using
FANCD2 antibodies. The ubiquitylation of FANCD2, detectable by a product with reduced mobility, is diminished in DK0064 (ATR–SS) and CV1720
cells compared to WT cells. E) Cells were exposed to 5 mM HU and examined for the percentage of cells showing.5 53BP1 foci at 2 h post exposure.
53BP1 foci formation is reduced in DK0064 (ATR–SS) and CV1720 cells compared to WT cells. F–I) The indicated cells were processed by WB using
ATRIP and ATR–Deficient Seckel Syndrome Patients
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observed a pronounced p-Chk1 band in WT LBLs but not in
CV1720 cells although Chk1 levels were similar in the two lines
(Figure 1C). These results provide strong evidence that CV1720
show impaired ATR–dependent substrate phosphorylation.
A further ATR–dependent response is mono-ubiquitylation of
FANCD2 following exposure to HU [28]. Mono-ubiquitinated
FANCD2 can be detected by the presence of a slowly migrating
isoform of FANCD2 generated post exposure to 3 mM HU.
Whilst such a product was detected in WT cell extracts, it was
absent in CV1720 and DK0064 (ATR–SS) cell extracts
(Figure 1D). Finally, ATR also regulates the formation of 53BP1
foci following replication fork stalling via a Chk1-dependent
process. We observed a failure to form 53BP1 foci following
exposure to 5 mM HU in CV1720 and DK0064 (ATR–SS) LBLs
in contrast to WT LBLs (Figure 1E), consistent with the
diminished levels of p-Chk1 observed in CV1720 cells.
Collectively, these studies provide strong evidence that CV1720
cells are defective in an upstream step of the ATR–dependent
signalling response defining them as distinct to the majority of
previously characterised SS cell lines, which, though defective in
UV-induced G2/M checkpoint arrest, are proficient in upstream
steps of the ATR signalling response [25].
Reduced ATR and ATRIP protein expression in CV1720
cells
Given the overlapping cellular phenotype between CV1720 and
DK0064 (ATR–SS) cells, we examined CV1720 cells for
expression of ATR and ATRIP protein by Western Blotting.
Strikingly, we observed markedly reduced levels of both ATR and
ATRIP in CV1720 cells (Figure 1F). Since ATRIP stabilises ATR,
this does not distinguish whether the primary defect lies in ATR or
ATRIP and indeed a similar reduced level of ATR and ATRIP
was observed in DK0064 (ATR–SS) cells (Figure 1G). Signifi-
cantly, we observed reduced ATRIP and ATR in both parental
LBLs (CV1780 and CV1783), which was approximately 50% of
the level in WT LBLs (Figure 1G–1I).
Sequencing analysis reveals mutational changes in ATRIP
in CV1720 cells
To examine whether the causal genetic defect in CV1720 lies in
ATR or ATRIP, we carried out sequencing of the two genes. First,
we undertook PCR-based gDNA sequencing of the 47 exons and
neighbouring exon-intron boundaries of the human ATR gene
from CV1720 cells and failed to observe any mutational changes
likely to be of functional significance. Next, we undertook gDNA
sequencing of ATRIP exons and observed a heterozygous
mutational change, c.2278C.T, in exon12 which generated a
stop codon predicting a truncated protein at position arginine 760
(p.Arg760*) (Figure S3). However, no mutational changes in any
other exons were identified although we detected several novel
intronic changes that could potentially impact on splicing (Table
S1). Significantly, the c.2278C.T mutational change was
observed as a heterozygous change in the patient’s mother but
not in the father (Figure S3).
We also performed RT-PCR sequencing of ATRIP cDNA from
CV1720 and both parents. These analyses revealed a low level of a
smeared PCR product following amplification of the 59ATRIP
cDNA region using patient but not control cDNA (data not
shown). Following multiple analyses, we found specifically that
RT-PCR amplification using primers located in exons 1 and 4,
reproducibly yielded a smeared product from CV1720 cDNA with
discrete bands at 458 bp (the expected product size) and 325 bp
whereas only the 458 bp product was observed using cDNA from
WT cells (Figure 2A). Direct sequencing of the gel purified smaller
(325 bp) and full-length (458 bp) RT-PCR products showed that
the small fragment specifically lacked exon 2. Sequencing analysis
of the RT-PCR product of CV1720 cDNA using the same primers
revealed the predicted double sequence with the product lacking
exon 2 being less than 50% of the product containing exon 2
(Figure 2B). It is notable that there were also some PCR products
larger than the full length product although a discrete band was
not evident. In sequencing the RT-PCR product, we observed
some that harboured intron 2 sequences although these repre-
sented a minor product relative to that lacking exon 2.
Collectively, these findings strongly suggested that there could be
mis-splicing in CV1720 cells with loss of exon 2 being the major
product.
To assess this further, qRT-PCR was undertaken using sets of
primers that allow selective amplification of the WT and mutant
products (c.2278C.T mutant as well as the mis-spliced product).
The aim was to determine if the mis-spliced product originated
from the paternal allele and if it impacted upon the transcript
level. Primer pairs, P1 and P3C, located in exons 12 and 13,
respectively, allow selective amplification of the WT (paternal)
c.2278C allele whilst primers P2 and P3C selectively amplify the
mutated (maternal) c. 2278C.T allele (Figure 2C). As expected,
the mutant (c.2278C.T)-allele-specific PCR product (right
columns, red bars) was only detected in the patient and mother
whereas the WT-specific PCR product (left columns, blue bars)
was detected in all samples, demonstrating that the primers
distinguished the two alleles (Figure 2C). The results also showed
that the c.2278C.T and the WT (c.2278C) alleles were expressed
at nearly equal levels (normalised against HPRT1) in the mother
(compare blue and red bars labelled ‘mother’ in Figure 2C),
suggesting that the c.2278C.T ATRIP mRNA is not subject to
nonsense mediated RNA decay (NMD) (Figure 2C).
To evaluate the expression level of the mis-spliced ATRIP
mRNA, we designed primers located at the exon 2/exon 3
boundary (primer P4) and within exon 3 (primer 6C) to allow
selective amplification of the correctly spliced mRNA (Figure 2D);
primers located at the exon 1/exon 3 boundary (primer P5) and
within exon 3 (primer 6C) selectively amplify the mis-spliced
mRNA. Whilst the correctly spliced product was amplified to
similar (although slightly different) extents from father, mother and
patient mRNA (compare the column heights, left panel in
Figure 2D), the mis-spliced product was more abundant in the
patient and father, suggesting that mis-splicing is a consequence of
a mutational change linked to the paternal allele (compare the
column heights, right panel in Figure 2D). Since we observed
nearly equal expression levels of the wild type (c.2278C) and
mutant (c.2278C.T) alleles in the mother (Figure 2C, compare
the right and left panels), we considered that the PCR products
derived from the mother using primers P4/P6C or P5/P6C would
ATRIP or ATR antibodies. MCM2 was used as a loading control. F shows the analysis of a range of protein levels for accurate comparison. CV1720
(patient) cells show markedly reduced ATR and ATRIP protein levels. G shows that both parental lines have approximately half the level of ATR and
ATRIP compared to two WT cell lines. DK0064 (ATR–SS) and CV1720 cells, in contrast, have more dramatically reduced ATR and ATRIP protein levels.
50 ug protein was loaded. WT in all panels was GM2188. Patient, mother and father were as shown in panel A. H and I show the quantification of
ATRIP and ATR protein levels from at least three independent WB experiments.
doi:10.1371/journal.pgen.1002945.g001
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be equally derived from the c.2278C and c.2278C.T alleles,
which have, therefore, been depicted as equal sized contributions
(shown in red or blue in mother columns in Figure 2D). Similarly,
the mutant c.2278C.T allele is likely to be expressed at an equal
level in the patient as in the mother (shown in red in patient
columns in Figure 2D). Based on these assumptions, we estimated
that the normally spliced WT mRNA is reduced to around 1/4 of
the WT level in the patient and to 3/4 in the father (shown in blue
in the left hand panel in Figure 2D). Assuming that the
c.2278C.T allele is fully inactivated (see below), the patient
Figure 2. Identification of mutational changes in ATRIP in CV1720. A) Upper panel shows primer pairs used to distinguish cDNA products
encompassing or lacking exon 2. Lower panel shows RT-PCR products obtained using the primers shown in the upper panel. RT-PCR from patient
CV1720 generated a smeared product with a defined band of 458 bp, as observed in WT cells, and a weaker band of 325 bp. The latter band was not
detected using cDNA from WT cells (MRC5). A similar single 458 bp band was obtained using the same primers with cDNA derived from a distinct
wild type cell line (GM2188; data not shown). (B) Sequencing of the RT-PCR products derived from WT (MRC5) and patient (CV1720) cells. A double
sequence pattern at the exon 2–3 boundary is observed using patient CV1720 cDNA. C) Selective quantitative amplification of the WT or 2278C.T
ATRIP alleles. Primers located in ATRIP exon 12 and 13 were designed to selectively amplify the WT (c.2278C) (P1 and P3C) versus the mutated
(c.2278C.T) (P2 and P3C) alleles. The WT PCR product is shown in blue and the c.2278C.T PCR product in red. The exon 12 mutated allele is only
observed in the patient and mother cDNA whilst the WT allele is observed in the patient, mother and father cDNA although the level is reduced in the
patient and mother. D) qRT-PCR analysis of ATRIP splicing variants from patient CV1720 and parental cells. qRT-PCR analysis of the level of the
normally spliced (encompassing exons 1-2-3) and the aberrantly spliced (Dexon2) ATRIP cDNA in the patient and parent cells. PCR primers were
designed at the exon2-exon3 or exon1-exon3 boundaries to selectively amplify the splicing variants. Transcripts from HPRT1 were used as a
quantification control. The correctly spliced transcript from the paternal allele of the patient (wild type c.2278C, blue fraction in the cumulative bar
labelled, ‘patient’, at the left panel) was estimated to be,25% of the normal level. (E) The mis-spliced paternal allele is subject to nonsense mediated
mRNA decay (NMD). Cycleave-qPCR confirmed that the ATRIP c.2278C.T mutant allele was expressed exclusively in the patient and the mother. The
ATRIP exon12-13 fragment was amplified with PCR primers P7/P8 as shown in the figure. A set of fluorescent probes were used to distinguish the WT
versus c.2278C.T allele (probe1 and probe2, respectively). In the patient, the paternal mRNA transcript level (emerald lines) is low because of NMD
(top left). Puromycin treatment eliminated the NMD and the paternal transcript level returned to the normal level. In all panels WT represented MRC5,
patient was CV1720 and parents were as shown in Figure 1A.
doi:10.1371/journal.pgen.1002945.g002
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therefore has around 25% of ATRIP activity compared to a
normal individual.
The findings above suggested that the mis-spliced mRNA,
which generates an out of frame cDNA, is subject to NMD. To
examine this and substantiate our findings, qRT-PCR was also
carried out using fluorescent cycleave probes with or without
exposure to puromycin, an antibiotic which prevents NMD
(Figure 2E) [29]. Primers (P7 and P8) and fluorescent probes
(probe 1 and 2) were designed to allow amplification of a product
encompassing exon 12–13 that distinguished the maternal (probe
2) from the paternal (probe 1) allele. We confirmed detection of
the c.2278C.T allele exclusively in the patient and mother as
well as the WT allele in all samples (Figure 2E). In the mother,
the wild type (c.2278C) and mutant (c.2278C.T) signals were
detected at equal levels regardless of whether puromycin was
added, indicating that the alleles are equally expressed and are
not subjected to NMD. In patient CV1720, the WT product was
reduced relative to the mutant product in the absence of
puromycin but was at similar levels in the presence of puromycin
(Figure 2E). These findings are consistent with the notion that
the mRNA expressed from the parental allele is aberrantly
spliced and partially subject to NMD. Perhaps surprisingly, we
did not detect any obvious difference of the WT product
following puromycin treatment in the father; however, in this
case, we anticipate a 25% decreased product, which is unlikely to
be detected without an internal control. However, despite this,
there was evidence for abnormal splicing in the paternal cDNA
from analysis of the PCR products spanning exons 1–3
(Figure 2B, 2D).
Finally, to gain insight into the basis underlying mis-splicing, we
sequenced introns 1 and 2 from the patient, mother, and father
and identified a previously unreported mutational change in intron
2, 13 bp from the intron-exon 2 boundary in the patient and
paternal gDNA (Table S1). However, given the modest impact on
splicing we did not attempt to examine whether this represented
the causal mutational change affecting splicing.
Arg760* ATRIP does not promote ATR–dependent G2/M
arrest and reduces ATR–ATRIP interaction
It is likely that ATRIP c.2278C.T causes an impacting
mutational change since the low levels of ATRIP protein (10–
20% WT levels) in CV1720 cells suggest that p.R760* ATRIP is
unstable (given that the mRNA level of this allele is normal). To
substantiate that p.R760* expression impairs the ATR–dependent
response to DNA damage, we examined whether its expression
could complement the G2/M checkpoint defect of CV1720 cells.
We also examined whether p.R760* might exert a dominant
negative impact (since this represented a possible explanation for
the low ATRIP protein level in CV1720 cells). The c.2278C.T
mutational change was introduced into ATRIP cDNA by site
directed mutagenesis. cDNA encoding WT ATRIP and/or R760*
ATRIP was transiently transfected into LBLs and G2/M
checkpoint arrest examined at 2 h post exposure to 5 Jm22 UV.
Consistent with previous findings, WT but not CV1720 cells
showed a G2/M checkpoint arrest (Figure 3A). Whilst transfection
with WT ATRIP cDNA completely rescued the G2/M checkpoint
defect of CV1720 cells, no correction was observed in CV1720
cells following expression of c.2278C.T ATRIP cDNA (encoding
R760* ATRIP). Surprisingly, expression of WT ATRIP cDNA also
corrected the G2/M checkpoint defect in DK0064 (ATR–SS)
cells, which we propose could result from elevated ATRIP
expression causing stabilisation of residual ATR protein, since
ATR–SS cells have low ATR and ATRIP expression. Significant-
ly, c.2278C.T ATRIP cDNA was unable to rescue ATR–SS cells.
Finally expression of c.2278C.T ATRIP cDNA in WT cells did
not affect G2/M checkpoint arrest demonstrating that p.R760*
ATRIP does not exert a dominant negative impact. Collectively,
we conclude that p.R760* ATRIP impacts upon ATRIP function.
Next we examined how loss of the ATRIP C-terminus might
impact upon ATRIP function. Two studies have previously
observed that the C-terminal region of ATRIP is required for
interaction with ATR [21,30]. Falck et al [30] reported that ATR–
ATRIP interaction required the C-terminal 32 amino-acids of
ATRIP (769–791) whilst Ball et al [21] found that interaction was
abolished in a protein that lacked exon 11, which encompasses
amino-acids 658–684. Arg760 lies close to these regions. To
examine whether p.R760* ATRIP can interact with ATR, HA-
tagged WT or c.2278C.T (ATRIP R760*) cDNA was co-
expressed with untagged WT ATR cDNA in HEK293 cells.
Following IP with HA-agarose, the level of co-immunoprecipitated
ATR was assessed by Western Blotting. Although there was a low
level of non-specific ATR binding to the HA beads, the level of
ATR present after HA-R760* ATRIP expression (derived from
c.2278C.T ATRIP cDNA) was substantially lower than after HA-
WT ATRIP expression (Figure 3B left panel). Both WT and
R760* ATRIP were efficiently expressed, however (Figure 3B
right panel). Thus, we conclude that R760* impairs the binding of
ATRIP to ATR.
Identification of further patients with mutations in ATR
In the course of our functional characterisation of cell lines from
SS patients, we examined LBLs derived from two SS patients, 27-
4BI and 19-8BI (see Figure 4A, Figure S4, and Table 1 for clinical
details). Western Blotting revealed that both cell lines displayed
substantially reduced ATR protein whilst showing normal
expression of other DNA damage response components, including
CtIP, TOPBP1 and RAD17 (Figure 4B). 27-4BI also had reduced
ATRIP levels. Additionally, the 27-4BI cell line expressed normal
levels of PCNT, excluding MOPD type II as a potential genetic
diagnosis, since most of these patients exhibit severely reduced
PCNT expression. These findings raised the possibility that the
patients could harbour mutations affecting ATR or ATRIP
expression. Sequencing of ATR cDNA revealed the same
c.3477G.T mutational change in both patients (Figure S5A).
This change causes an amino acid substitution, p.Met1159Ile,
which lies within a conserved UME (NUC010) domain of ATR.
UME domains, and particularly the methionine residue within the
domain, are highly conserved in ATR species, including yeast
although their function is unknown (Figure 4C and 4D).
The second ATR mutation identified was c.6897+464C.
G;p.Val2300Gly fs75*, which, surprisingly, was also present in
both patients. RT-PCR sequencing showed that a 142 bp
sequence, which originated from a repeat region present in intron
40, was inserted at the boundary between exon 40 and 41 in both
patients (Figure S5C). Genomic sequencing revealed the presence
of a single C.G mutation in intron 40, which generates a
preferred splice signal causing insertion of the intron sequence to
the start of exon 41 (Figure S5D for further details). This insertion
causes a frameshift and the generation of a stop codon at c.6978 in
exon 41. Sequencing of ATRIP cDNA in patient 27-4BI failed to
reveal any mutational changes. Thus, our findings provide strong
evidence that mutational changes in ATR underlie the reduced
ATR/ATRIP expression observed in both patients.
To verify that these mutational changes impact upon ATR
function, we examined whether 27-4BI cells could activate UV-
induced ATR–dependent G2/M checkpoint arrest. Significantly,
we observed an inability to activate UV-induced G2/M check-
point arrest in 27-4BI cells similar to that observed in DK0064
ATRIP and ATR–Deficient Seckel Syndrome Patients
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(ATR–SS) cells (Figure 5A) [7]. Checkpoint arrest after exposure
to ionising radiation was activated normally. Additionally, we
examined the phosphorylation of a range of ATR substrates
following exposure to 0.5 mM HU and observed impaired
phosphorylation in both 27-4BI and 19-8BI cells (Figure 5B).
Collectively, these functional data substantiate a deficiency in the
ATR–dependent DNA damage response in LBLs from these two
cases. Thus, we conclude that both patients represent further
ATR–SS patients.
Discussion
Although the first causal defect for SS was identified as ATR in
2003, further patients with mutations in ATR have not been
reported [7]. SS patients are characterised by microcephaly and
growth delay, features also observed in other microcephalic,
primordial dwarfism syndromes including MOPD type II and
MGS. Given that all ATR–SS patients to date share consanguinity,
there are limitations in defining the spectrum of clinical features
conferred by ATR deficiency to support a clinical distinction
between ATR–SS and related disorders such as MOPD type II and
MGS as well as other sub-classes of SS [1–3,31].
Here, we describe the novel identification of a patient mutated
in ATRIP, the binding partner of ATR. Thus, we identify ATRIP
as a new causal gene for SS. The mutational change in one ATRIP
allele lies within a region previously suggested to be required for
interaction with ATR, which is consolidated by our work [21,30].
We demonstrate that the second allele is abnormally spliced causing
a reduction in ATRIP mRNA from that allele. qRT-PCR analysis
suggested that there could be 25% residual WT ATRIP expressed in
the patient cells. Consistent with this, we routinely observed ,10–
20% of WT ATRIP protein in CV1720 cells by Western Blotting,
although the level was variable between preparations. Although not
examined in detail, there appeared to be a correlation between
proliferation status and ATRIP levels, with the levels decreasing as
proliferation slowed. Thus, differences in the proliferative state of
cells at the time of analysis may underlie the apparent difference
betweenWestern Blotting and qRT-PCR analysis. Notwithstanding
some limitations in quantification, the patient clinical features were
marked despite,10–20% residual ATRIP expression. Similarly, in
patient DK0064, residual ATR protein can be readily detected [7].
Thus, we conclude that reduced but detectable levels of ATR/
ATRIP protein can confer a clinical phenotype.
Additionally, we identify two further SS patients with ATR
mutations in two unrelated families native to the UK. Interest-
ingly, despite being unrelated, 27-4BI and 19-8BI carry the same
compound heterozygous mutations, possibly representing founder
mutations in the UK population.
Figure 3. WT ATRIP cDNA but not cDNA encoding p.Arg760* ATRIP complements the G2/M checkpoint defect in CV1720 cells, and
p.Arg760*ATRIP impairs ATR–ATRIP protein interaction. A) Analysis of the G2/M checkpoint defect in CV1720 cells following expression of
ATRIP cDNA. G2/M checkpoint arrest was examined 2 h post exposure to 5 Jm22 UV. As shown in Figure 1A, WT cells showed proficient checkpoint
arrest whilst DK0064 (ATR–SS) and CV1720 (patient) cells are unable to undergo arrest. Expression of WT ATRIP cDNA restored the ability of CV1720
(patient) and DK0064 (ATR–SS) to undergo checkpoint arrest but this was not observed following transfection of cDNA encoding R760* ATRIP.
Significantly, expression of ATRIP R760* did not impair checkpoint arrest in WT cells verifying that it does not exert a dominant negative impact.
Results represent the mean and SD of three experiments. WT cells were GM2188. ATR–SS represents DK0064 and patient, CV1720. B) R760* ATRIP
impairs ATR–ATRIP interaction. Crude lysates were prepared from HEK293T cells and either mock transfected (lane1), transfected with HA-tagged WT
ATRIP cDNA (lane2), or R760* ATRIP cDNA (lane3) (generating p.Arg760* ATRIP protein) together with ATR cDNA. The extracts were
immunoprecipitated with agarose-conjugated rabbit anti-HA-tag antibody (MBL). Interaction with ATR was examined by immunoblotting with
ATR antibodies (left panel). Immunoblotting using the HA-tag (ATRIP; right panel) verified expression of the appropriately sized ATRIP in the samples.
33% of the crude lysate was loaded; IP, immunoprecipitate.
doi:10.1371/journal.pgen.1002945.g003
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All four ATR/ATRIP patients displayed severe microcephaly
and growth delay (Table 1). All patients also displayed microgna-
thia, receding forehead, dental crowding and microtia with small
or absent lobes (Figure 4A). Interestingly, an MRI scan of the
ATRIP–SS patient revealed an abnormally small pituitary with
absent fossa, which could contribute to the delayed growth
observed (Figure S1). In distinction to the original ATR–SS
patient (DK0064), patients 27-4BI and 19-8BI showed more
marked skeletal abnormalities including digital features and
aberrant patellae suggesting that ATR deficiency can have a
detrimental impact on bone development (Table 1, Figure S4)
[32]. Interestingly, aberrant patellae is a clinical feature commonly
exhibited by MGS patients suggestive of a biological overlap
between the ATR checkpoint pathway and the replication
machinery during skeletal development and maintenance. In
keeping with this, characterisation of a mouse model harbouring
the same mutational change identified in the original ATR–SS
patient (DK0064) revealed marked bone abnormalities including
kyphosis and osteoporosis [32]. Our findings suggest that ATR–
ATRIP SS shows more overlap with MGS than previously
recognised (Table 2). However, whereas ATR–ATRIP SS patients
tend to have very marked microcephaly, growth delay, dental
crowding, small ears and less severe skeletal abnormalities, the
spectrum for MGS tends to be less marked microcephaly and
growth delay but a striking impact on skeletal development.
Nonetheless, there does not appear to be an absolute clinical
divide between these two disorders. Significantly, these overlap-
ping clinical features could reflect the fact that both ATR/ATRIP
Figure 4. Patients 27-4BI and 19-8BI have reduced ATR and ATRIP expression and mutations in ATR. A) Photographs of patient included
with informed consent of parent. B) Cell extracts (50 mg) from LBLs derived from WT (IM257), patient 27-4BI or patient 19-8BI were immunoblotted
using the indicated antibodies. Reduced expression of ATR was observed in both patients. 27-4BI also had reduced ATRIP expression. C) Structure of
ATR showing the site of the mutations identified and the UME domain. D) The UME domain is conserved between species and the methionine
residue within this domain is conserved in yeast.
doi:10.1371/journal.pgen.1002945.g004
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and the origin licensing complex play an essential role in
promoting efficient replication and recovery from fork stalling,
which may be vital during developmental stages involving rapid
replication [13].
In summary, we provide the first report of a SS patient with
mutations in ATRIP, defining a further novel genetic defect for this
disorder, and describe two additional patients native to the UK,
with mutations in ATR. The description of multiple ATR–ATRIP
patients allows us to define a spectrum of clinical features conferred
by ATR–ATRIP mutations. The clinical characteristics include
severe microcephaly and growth delay, small or absent ear lobes,
micrognathia and dental crowding. In addition, the novel ATR–
mutated cases described here expand the clinical impact of impaired
ATR–function to include more marked skeletal involvement.
Methods
Ethics Statement
Ethical approval for the research was granted by the School of
Life Sciences Research Governance Committee, University of
Sussex. Informed consent was obtained and clinical investigations
were conducted according to the principles expressed in the
Declaration of Helsinki. Patient material was gathered under
conditions of the Human Tissue Authority (HTA licence number
12119).
Patients and cell lines
CV1720 is a SS patient of Gujarati-Indian origin. Patients 27-
4BI and 19-8BI are English. The clinical features are described in
Figure 5. LBLs from patient 27-4BI and 19-8BI showed impaired ATR–dependent damage responses. A) 27-4BI cells were examined for
their ability to activate G2/M checkpoint arrest at 4 h following exposure to 7 Jm22 UV. In contrast to WT cells (GM2188), no significant arrest was
observed in 27-4BI cells. The checkpoint response to ionizing radiation, which is ATM rather than ATR dependent, was normal. B) LBLs derived from
patients 27-4BI and 19-8BI were examined for their ability to phosphorylate the indicated ATR substrates at 1 h following exposure to 0.5 mM HU. WT
represents IM257. 27-4BI and control LBLs have a similar cell cycle profile demonstrating that the lack of ATR substrate phosphorylation cannot be
attributed to the lack of S phase cells (Figure S2).
doi:10.1371/journal.pgen.1002945.g005
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Table 1. Lymphoblastoid cell lines (LBLs) were derived from blood
following EBV transformation. WT LBLs were GM2188 or
LB197 as indicated. All LBLs were grown in RPMI medium
supplemented with 10% foetal calf serum, penicillin, and
streptomycin. Transfection with ATRIP cDNA was with Genejuice
Transfection Reagent (Novagen, Merck Millipore, UK) following
the manufacturers protocol.
qRT–PCR. Transcript levels of the ATRIP–c.2278C (normal)
and ATRIP–c.2278C.T (p.Arg760*) alleles in LBLs from patient
CV1720, and the parents were determined by the cycleave
quantitative real time PCR (Cycleave-qPCR, TaKaRa Co. Ltd,
Kyoto Japan) as well as standard site specific q-PCR (carried out in
triplicate). Transcripts from the HPRT1 allele were used as a
quantification control. In the Cycleave qPCR, RNaseH sensitive
fluorescent probes that specifically recognize the c.2278C and
c.2278C.T alleles were used for the assay. qPCR results were
analyzed by the DDCTmethod. qPCR primers and probes used for
the assay are listed below. (172F, 59-CTTCACTGCCGAC-
GACCTGG-39; 191R, 59-TTTGCTCGTTCACTGGTCTG-39;
P1, 59-GGGGTCAGCATGCTCATCC-39; P2, 59-GGGGGTC-
AGCATGCTCATCT-39; P3C, 59-ACCTCGGGGTCTTCCA-
CATC-39; P4, 59- -39; P5, 59- -39; P6C, 59- -39; P7, 59-GCC-
TATCGCAGAAGGACAAG-39; P8, 59-GGGTCTTCCACAT-
CGGTTTC-39; probe1 for c.2278C, 59Eclipse-CCCTC(rG)GAT-
39FAM; probe2 for c.2278C, 59Eclipse- GCCCTC(rA)GA-39ROX)
Co-immunoprecipitation. To investigate the interaction of
the ATRIP proteins with ATR, HEK293T cells were transfected
with the HA-tagged ATRIP cDNA expressing plasmids (wild type
and 2278C.T ATRIP) together with ATR cDNA, followed by
24 h incubation. Whole cell lysates were prepared using CelLytic
Nuclear Extraction Kit (Sigma, St. Louis). Co-immunoprecipita-
tion was performed using rabbit anti-HA antibody-conjugated
agarose beads (MBL, Nagoya, Japan). Western blotting was
carried out using ATR or anti-HA (detecting HA-tagged ATRIP)
antibodies. Anti-ATR was N19 (Santa Cruz, Santa Cruz) at 1:200
dilution. Anti-HA-tag antibody, 132-3 (MBL, Nagoya, Japan), was
used at 1:1000 dilution.
Immunofluorescence for analysis of cH2AX and 53BP1
staining
Cells were cytospun onto slides, fixed with 3% formaldehyde for
10 min and permeabilized in 0.5% Triton-X100. After antibody
treatment and staining with 4,6-diamidino-2-phenylindole (DAPI),
coverslips were mounted in Vectashield mounting medium (Vector
Laboratories, Burlingame). Samples were incubated with primary
antibodies for c-H2AX (Millipore, Billerica) or 53BP1 (Bethyl,
Montgomery). Secondary antibodies were from Sigma (St. Louis).
Western blotting
Cells were lysed for one hour in IPLB (50 mM Tris-HCl,
150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 25 mM NaF,
25 mM b-glycerolphosphate, 0.1 mM NaOrthovanadate, 0.2%
Triton X-100, 0.3% NP-40, plus protease inhibitor cocktail
(Roche, Basel) at 4uC, centrifuged at 13,000 rpm for 10 minutes.
The soluble fraction was subjected to SDS-PAGE and transferred
to a nitrocellulose membrane for protein detection.
Antibodies raised against ATR, CHK1 (FL476) and MCM2
(N19) were from Santa Cruz (Santa Cruz). Anti-FANCD2, ATRIP
and phospho-Chk1 (Ser317) antibodies were from Novus (Lit-
tleton), Bethyl (Montgomery), and Cell Signaling (Beverly,
Woburn), respectively.
G2/M checkpoint arrest
Cells were exposed to 5 or 7 Jm22 UV, or 3Gy ionising
radiation and incubated for 2 or 4 hours (as indicated) in complete
medium containing 0.2 ug/ml Colcemid (Invitrogen, Carlsbad),
followed by processing for immunofluorescence as detailed above.
Mitotic cells were detected by a-Histone H3-pSer10 antibodies
(Millipore, Billerica) and cells were counterstained with DAPI.
Table 2. MGS and Seckel syndrome patient phenotypes.
ORC1 - MGS Pre-RC MGS ATR/ATRIP SS
Number of patients 10 25 4
OFC (cm)* 25.4 to 211 SD +1.7 to 25.0 SD 210 to 212 SD
Height (cm)* 24.5 to 29.6 SD 20.4 to 26.4 SD 25 to 28 SD
Weight (kg)* 0.8 to 211 SD 20.3 to 29.9 SD 23.3 to 28 SD
Intellectual disability Ranges from none to mild/moderate None Developmental delay (2/4)
Facial Features Small and abnormal ears (9/10),
micrognathia (5/10), down slanted
palpebral fissures (1/10)
Small and abnormal ears(25/25),
micrognathia (20/25), down slanted
palpebral fissures (8/25)
Small and/or abnormal ears (4/4),
micrognathia (4/4), receding forehead (4/4),
prominent nose (4/4), short palpebral fissures
(2/4)
Skeletal abnormalities Delayed bone age (3/10), Slender long
bones (2/10) , absent patellae (6/10),
genu recurvatum (4/10)
Delayed bone age (11/25), slender
long bones, absent patellae (24/25)
Delayed bone age (1/4), 5th finger
clinodactyly (2/4), symmetric dwarfism (3/4),
small/abnormal patellae (2/4), kyphosis (1/4),
hip abnormality (2/4), narrow pelvis (iliac
blades) (1/4)
MRI Normal in 2 patients examined NA Generalised cerebral atrophy, delayed
myelination, abnormal gyration (2 patients
examined)
Other High pitched voice (1/10), full lips (7/10),
cryptochordism (2/4 examined), mammary
hypoplasia (2/2 examined), feeding and
respiratory problems during infancy (8/10)
Full lips (14/25), cryptochordism (7/14
examined), mammary hypoplasia (8/8
examined), feeding (20/25) and respiratory
(9/25) problems during infancy
Dental crowding (4/4), feeding and
respiratory problems during infancy (1/4)
*standard deviations from the age-related normal population mean, NA= not assessed.
MGS data from [13,14] [33,34].
doi:10.1371/journal.pgen.1002945.t002
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Supporting Information
Figure S1 Photograph of limbs and MRI scan of patient
CV1720. Left hand photograph showing hands and feet. Right
hand photograph shows an MRI scan where a small pituitary is
evident.
(TIF)
Figure S2 Cell cycle analysis of WT, DK0064 (ATR–SS), 27-
4BI, and CV1720 patient LBLs. A) Asynchronous growing
cultures of WT, DK0064 (ATR–SS), 27-4BI and CV1720 patient
cells were pelleted, fixed in 70% ice-cold ethanol and stained with
propidium iodide prior to FACs analysis. Populations were gated
and the proportion of cells in G1, S and G2/M phases of the cell
cycle measured. B) WT, DK0064 (ATR–SS), 27-4BI and CV1720
patient cells were treated with nocodazole for 16 h and then fixed
and analysed as in a). C) Asynchronous growing cultures of WT,
DK0064 (ATR–SS), 27-4BI and CV1720 patient cells were pulse-
labelled with 50 mM BrdU for 1 h. Cells were then fixed in 70%
ice-cold ethanol and processed for BrdU FACs analysis as
described in Bicknell et al, 2011 [13]. The proportion of cells in
S phase were gated and measured. Each graph represents the
mean of three independent experiments. The error bars represent
the standard deviation.
(TIF)
Figure S3 Identification of a truncating mutation in ATRIP in
patient, CV1720. Genomic DNA sequencing of ATRIP exons
showed that patient CV1720 and the unaffected mother, CV1780,
are heterozygous for a c.2278C.T mutational change in exon12
of ATRIP. The father has a WT sequence at this site. 2278C.T
generates a primary stop codon predicting a truncated protein at
position arginine 760 (p.R760*). WT sequence shown in blue, the
mutation is shown in Red.
(TIF)
Figure S4 Photographs of patients 27-4BI and 19-8BI. A) Shows
abnormal digits of patient 27-4BI. B) Copper beaten appearance
of skull of patient 19-8BI. C) Frontal and Lateral view of left knee
of patient 19-8BI showing an absence of ossification of the patella.
(TIF)
Figure S5 Mutational changes observed in ATR in patients 27-
4BI and 19-8BI. A) c.3477G.T mutational change in patients 27-
4BI and 19-8BI. RT-PCR sequencing revealed a heterozygous
3477G.T mutational change in both patients causing an amino
acid substitution, p.Met1159Ile, which lies within a conserved
UME (NUC010) domain of ATR. B) A double sequence was
observed at the boundary between exons 40 and 41 in both
patients. Sequencing showed that the double sequence was caused
by insertion of a 142 bp region from intron 40. C) A C to G
mutational change was observed in intron 41 of both patients
converting the sequence CAGCT to CAGGT, a splice site. The
insertion causes a frameshift and a stop codon at p.Val2300-
Glyfs*75. D) Diagram showing the likely origin of the insertion
observed at the exon 40/41 boundary. Sequencing of intron 40
revealed a C.G mutation as indicated creating a cryptic splice site
causing splicing of exon 40 to the indicated intronic sequence
(which represents an Alu repeat sequence). Thus one ATR allele of
the patients harbours a 142 nucleotide insertion between exons 40
and 41. Exons 40 and 41 are highlighted in green and the inserted
intronic sequence is shown in red. The intronic C.G change is
highlighted in red. The insertion causes a frameshift and a stop
codon at c.6978 in exon 41.
(TIF)
Table S1 The table shows the position of single nucleotide
polymorphisms identified in intron 1 and 2 in the patient and
parental genomic DNA. * The contig position is defined as the
position of the single nucleotide variant (SNV) on the contig
(NT_022517.17) when counting from the first base (base
position = 1). **rs# is the NCBI’s reference SNP ID. *** minor
allele (indicated as a base) and its frequency (MAF) (second most
frequent allele) in a default global population reported in dbSNP
database (1000 Genome phase 1, May 2011). N.A. not
available.
(DOCX)
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